Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents

Journal of Cancer Research and Clinical Oncology

Volumn 129, Issue 12, 2003, Pages 709-718

  Mujoo, Kalpana ^a   Watanabe, Masayuki ^a,c   Nakamura, Junichi ^a,b   Khokhar, Abdul R ^a   Siddik, Zahid H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SAITAMA RED CROSS HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Cytotoxicity p21WAF1 CIP1 Drug resistance; p53 phosphorylation

Indexed keywords

BETA ACTIN; CELL DNA; CISPLATIN; PLATINUM 1,2 DIAMINOCYCLOHEXANEDIACETATE DICHLORIDE; PLATINUM DERIVATIVE; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; TRANSACTIVATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0346216966     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0480-4     Document Type: Article

References (54)

1. Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2:35-243
2. Appella E, Anderson CW (2001) Post-translational modifications and activations of p53 by genotoxic stresses. Eur J Biochem 268:2764-2772
3. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674-1677
4. Beesley JS, Ferry KV, Johnson SW, Godwin AK, Hamilton TC (1997) Ovarian cancer: biological basis of therapy. In: Langdon SM, Miller WM, Berchuck A (eds) Biology of female cancers. CRC Press, New York, pp 153-166
5. Boente MP, Hurteau J, Rodriguez GC, Bast RC, Berchuck A (1993) The biology of ovarian cancer. Curr Opin Oncol 5:900-907
6. Buick RN, Pullano R, Trent JM (1985) Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 45:3668-3676
7. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677-1679
8. Damia G, Sanchez Y, Erba E, Broggini M (2001) DNA damage induces p53-dependent down regulation of hCHK1. J Biol Chem 276:10641-10645
9. Dumaz N, Meek DW (1999) Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM 2. EMBO J 18:7002-7010
10. Eastman A, Schulte N (1998) Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27:4730-4734
11. Fan S, Chang JK, Smith ML, Duba D, Fornace AJ Jr, O'Connor PM (1997) Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogenmustard. Oncogene 14:2127-2136
12. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr, O'Connor PM (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649-1654
13. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886
14. Fritsche M, Haessler C, Brandner G (1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8:307-318
15. Giaccia AJ, Kastan MB (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes Develop 12:2973-2983
16. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89:3070-3074
17. Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H, Thompson JM (1995) Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: UK and Eire experience. Br J Cancer 72:1016-1019
18. Hagopian GS, Mills GB, Khokhar AR, Bast RC, Siddik ZH (1999) Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)- platinum(IV). Clin Cancer Res 5:655-663
19. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC (1993) Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53:5225-5232
20. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821-1828
21. Hirao H, Cheung A, Duncan G, Girard P-M, Elia AJ, Wakeham A, Okada H, Sarkissian T, Wong JA, Sakai T, Stanchina E, Bristow RG, Suda T, Lowe SW, Jeggo PA, Elledge SJ, Mak TW (2002) Chk2 is a tumor suppressor that regulates apoptosis in both ATM-dependent and ATM-independent manner. Mol Cell Biol 22:6521-6532
22. Jayaraman L, Prives C (1999) Covalent and noncovalent modifiers of the p53 protein. Cell Mol Life Sci 55:76-87
23. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC (1997) Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57:850-856
24. zKapoor M, Lozano G (1998) Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci USA 95:2834-2837
25. Kapoor M, Hamm R, Yan W, Taya Y, Lozano G (2000) Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene 19:358-364
26. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311
27. Kelley SL, Rozencweig M (1989) Resistance to platinum compounds: mechanisms and beyond. Eur J Can Clin Oncol 25:1135-1140
28. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, Taya Y, Gabrielli B, Chan D, Lees-Miller SP, Lavin MF (1998) ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 20:398-400
29. Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y, Terakawa N (2001) p53 gene status and chemosensitivity in ovarian cancer. Hum cell 14:165-171
30. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495
31. Laskin ND, Jackson SP (1999) Regulation of p53 in response to DNA damage. Oncogene 18:7644-7655
32. Lane DP (1992) p53: guardian of genome. Nature 358:15-16
33. Lee Y, McKinnon PJ (2000) ATM dependent apoptosis in the nervous system. Apoptosis 5:523-529
34. Lees-Miller SP, Chen YR, Anderson CW (1990) Human cells contain a DNA-activated protein kinase that phosphorylates simian virus 40 T antigen, mouse p53, and the human Ku autoantigen. Mol Cell Biol 10:6472-6481
35. WAF1/C1P1 cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 161:17-26
36. Lu H, Taya Y, Ikeda M, Levine AJ (1998) Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc Natl Acad Sci USA 95:6399-6402
37. Meek DW (1998) Multisite phosphorylation and the integration of stress signals at p53. Cell Signal 10:159-166
38. Meyn MS (1995) Ataxia telangiectasia and cellular response to DNA damage. Cancer Res 55:5991-6001
39. Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR (2000) The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 60:5390-5394
40. Price BD, Youmell MB (1996) The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res 56:246-250
41. Prives C (1998) Signaling to p53: breaking the MDM 2-p53 circuit. Cell 95:5-8
42. Rosenzweig KE, Youmell MB, Palayoor ST, Price BD (1997) Radiosensitization of human tumor cells by the phosphatidyl-inositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 3:1149-1156
43. Shieh SY, Ikeda M, Taya Y, Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM 2. Cell 91:325-334
44. Siddik ZH, Boxall FE, Harrap KR (1987) Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal Biochem 163:21-26
45. Siddik ZH, Mims B, Lozano G, Thai G (1998) Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 58:698-703
46. Siddik ZH, Hagopian GS, Thai G, Tomisaki S, Toyomasu T, Khokhar AR (1999) Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance. J Inorg Biochem 77:65-70
47. Sionov RV, Haupt Y (1999) The cellular response to p53: the decision between life and death. Oncogene 18:6145-6157
48. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C, Abraham RT (1999) A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Develop 13:152-157
49. Tsao YP, Huang SJ, Chang JL, Hsieh JT, Pong RC, Chen SL (1999) Adenovirus-mediated p21 WAF1/CIP1 (WAF1/SDII/CIP1) gene transfer induces apoptosis of human cervical cancer cell lines. J Virol 73:4983-4990
50. Vollano JF, Al-Baker S, Dabrowiak JC, Schurig JE (1987) Comparative antitumor studies on platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane. J Med Chem 30:716-719
51. Vousden KH (2002) Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 1602:47-59
52. Waldman T, Lengauer C, Kinzler KW, Vogelstein B (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 WAF1/CIP1. Nature 381:713-716
53. Weinberg RA (1991) Tumor suppressor genes. Science 254:1138-1146
54. Zhao H, Piwnica-Worms H (2001) ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 21:4129-4139